<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941524</url>
  </required_header>
  <id_info>
    <org_study_id>502-14-02215338-09873</org_study_id>
    <nct_id>NCT01941524</nct_id>
  </id_info>
  <brief_title>Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations</brief_title>
  <official_title>Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether there are differences in bioelectrical
      function (measured by amplitude integrated electroencephalography) and brain oxygenation
      (measured by near infrared spectroscopy) while and after instillation of two different
      surfactant preparations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients randomized to one of the treatment groups: 1) SRT with porcine preparation -
      poractant alfa; 2) SRT with bovine preparation - beractant. Continuous monitoring and
      simultaneous recordeding of 1) saturation (SpO2) and heart rate (HR) measured with pulse
      oximetry, cerebral tissue oxygenation measured with near-infrared spectroscopy,
      amplitude-integrated electroencephalography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 3, 2013</start_date>
  <completion_date type="Actual">June 20, 2015</completion_date>
  <primary_completion_date type="Actual">June 20, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral oxygenation</measure>
    <time_frame>4 hours after surfactant instillation</time_frame>
    <description>Cerebral tissue oxygenation measured with near-infrared spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain bioelectrical activity</measure>
    <time_frame>4 hours after surfactant instillation</time_frame>
    <description>Brain bioelectrical activity measured with amplitude-integrated electroencephalography (aEEG)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Poractant goup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beractant group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Newborns who will be monitored by aEEG and NIRS during beractant instillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poractant alfa instillation</intervention_name>
    <description>aEEG and NIRS monitoring during poractant alfa instilation</description>
    <arm_group_label>Poractant goup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beractant instillation</intervention_name>
    <description>aEEG and NRs monitoring during beractant instillation</description>
    <arm_group_label>Beractant group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  26-30 gestational age

          -  surfactant instillation

        Exclusion Criteria:

          -  congenital heart disease

          -  congenital central nervous disorder

          -  congenital genetic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Szczapa, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Poznan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neonatology</name>
      <address>
        <city>Poznan</city>
        <state>Great Poland</state>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Tomasz Szczapa</investigator_full_name>
    <investigator_title>doctor of medical science</investigator_title>
  </responsible_party>
  <keyword>Brain oxygenation</keyword>
  <keyword>NIRS</keyword>
  <keyword>aEEG</keyword>
  <keyword>surfactant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poractant alfa</mesh_term>
    <mesh_term>Beractant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

